Justificaiton and Approval for Development and Domestic Manufacture of Adjuvanted Recombinant Pandemic Influenza Vaccines
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- 75A50120D00002
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A50120D00002 Federal IDV award
- Awardee
- Sanofi Vaccines US Inc.
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- Place of performance
- Swiftwater, Pennsylvania 18370, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Limited/Sole Source Justification Notice publicizes the justification and approval for contract number 75A50120D00002 awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response on December 5, 2019. The contract provides for the development and domestic manufacture of adjuvanted, recombinant pandemic influenza vaccines to strengthen pandemic preparedness and response capabilities in the United States, though the awarded vendor and amount are unknown. The purpose of the justification and approval is to support this effort through a sole source contract given the need to develop and produce these specialized vaccines for pandemic response in a timely manner.
Notice text
The purpose of this notice is to publicize the Justification and Approval for contract number 75A50120D00002, Development and Domestic Manufacture of Adjuvanted, Recombinant Pandemic Influenza Vaccine, as required by FAR 6.305.
Awarded contract 75A50120D00002 to unknown vendor for unknown amount on 2019-12-05.
Files
| File | Type | Posted |
|---|---|---|
| SP JOFOC Adjuvant_Recombinant_Redacted.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity